Lysogene Announces Phase 3 Gene Therapy Platform Company Targeting Central Nervous System Diseases
May 20, 2021 at 12:00 pm EDT
Lysogene, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 25, 2021 at 09:00 am (CEST), at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008), France. The Shareholders’ Meeting documents and the voting form will be made available to Shareholders under the terms and conditions specified by current French regulations. The detailed procedures for participating to the meeting and send written questions are available in the meeting notice n° 2101874, which was published in the BALO (Journal Officiel) n° 60 dated May 19, 2021.